Urolithiasis, also known as kidney stones, are hard deposits made up of mineral and salt substances in the kidneys or urinary tract. Urolithiasis management devices are used for detecting, fragmenting and removing stones present in the kidneys or urinary tract. Some key urolithiasis management devices include intracorporeal lithotripters, ureteroscopes, nephroscopes, and ureteral stents. Intracorporeal lithotripters uses shock waves to break kidney stones into smaller fragments to pass out of the body naturally. Ureteroscopes and nephroscopes are used during ureteroscopy and percutaneous nephrolithotomy procedures respectively to locate and retrieve stones. Ureteral stents are placed after removal of stones to help heal and support the ureter.
One of the major drivers for growth of urolithiasis management devices market is rising prevalence of kidney stones globally. According to the American Urological Association, approximately 10% to 15% of the world’s population will have a kidney stone in their lifetime. Moreover, changing dietary and lifestyle habits such as low water intake, obesity are contributing to high risk of developing kidney stones. Another driver is development of newer minimally invasive procedures and technologically advanced devices for effective management of kidney stones. For instance, miniaturized ureteroscopes, nanopulse lithotripsy, and robotic surgery are emerging as alternatives to conventional procedures. In addition, growing healthcare expenditure and awareness about availability of treatment options is further expected to fuel the market growth over the forecast period.
The global Urolithiasis Management Devices Market Demand is segmented into lithotripters, ureteral stents, and kidney stones removal devices. Amongst these, the lithotripters segment held the largest market share in 2022 owing to the increasing preference for non-invasive procedures such as extracorporeal shock wave lithotripsy (ESWL) for treating kidney stones. The procedure utilizes high-energy shock waves to breakdown kidney stones without surgical incisions. Furthermore, advancements leading to the development of improved lithotripters with minimal side effects have augmented the growth of this segment.
Political: Policies regarding reimbursement coverage for urolithiasis treatment procedures influencing the adoption of management devices.
Economic: Rising healthcare expenditures on urolithiasis and favorable reimbursement scenarios driving the market growth.
Social: Increasing awareness about availability of minimally invasive procedures for treating kidney stones boosting the market.
Technological: Advancements in lithotripters and kidney stone removal devices facilitating non-invasive procedures with shorter recovery times fueling the market.
The global urolithiasis management devices market is expected to witness high growth, exhibiting CAGR of 4.8% over the forecast period, due to increasing geriatric population predisposed to kidney stone formation.
Regionally, North America dominated the market and accounted for the largest revenue share in 2023 owing to expanding patient pool, favorable reimbursement policies, and presence of major players in the region. However, Asia Pacific is anticipated to witness fastest growth due to growing healthcare infrastructure and rising medical tourism in countries such as India and China.
Key players operating in the urolithiasis management devices are Lumenis Ltd., Boston Scientific Corp, BD, Cook Medical, Karl Storz, Allengers Medical Systems, Inc, Olympus Corporation, Electro Medical Systems SA, Dornier MedTech GmbH, Direx Group., HealthTronics, Inc., CONMED Corporation., Applaud Medical, Inc., Potent Medical., and other prominent players. The global leaders are focusing on new product launches and strategic collaborations to strengthen their market position.